Khiron Life Sciences (CVE:KHRN) (OTCMKTS:KHRNF) VP of Compliance and former U.S. Drug Enforcement Administration (DEA), Chief of Pharmaceutical Investigations Matt Murphy shares why the company’s compliance philosophy has advantageous benefit for international expansion. Murphy explains that Khiron applies the DEA regulations that US pharmaceutical companies are mandated to comply with to regulate the company’s cannabis production in Colombia. Murphy believes that Khiron’s compliance with the strictest regulations gives it an edge as it expands its international operations. Crucially, when cannabis is de-scheduled in the US, Khiron will already be compliant with the likely cannabis regulatory standards. Murphy predicts that the pharmaceutical industry will intervene in the cannabis market in ways similar to the liquor industry’s engagement, once cannabis is legalized federally in the US.

James West:   Hey, welcome back. My guest in this segment is Matt Murphy; he’s the VP of Compliance for Khiron Life Sciences Corp., trading on the TSX Venture under the symbol KHRN. Matt, welcome back to the show.

Matt Murphy:  Thanks, Jim. Pleasure to be here.

James West:   Matt, give us an update: what’s happening down there in Colombia?

Ma

Cannabics Pharmaceuticals (OTCMKTS:CNBX) CEO Eyal Barad discusses the company’s plans to collect data on cannabinoids and cancer to create diagnostic tools and treatments for the disease. Barad sees Cannabics’ data as especially useful for doctors who prescribe cannabis therapies to cancer patients. Cannabics plans to further commercialize its diagnostic testing products and develop additional palliative products for the cancer market. Cannabics intends to test its products and collect data in Israel, the United States, and Germany, but remains interested in the Canadian medical cannabis market.

James West:   Eyal!

Eyal Barad:   Hi, how are you doing?

James West:   Fantastic, how are you doing?

Eyal Barad:     Good, James, how’s it going?

James West:   Eyal, are you on a laptop? Yeah, there we go.

Eyal Barad:   I’m actually on my phone out here in Israel. It’s almost 11:00 p.m., talking to you. how you guys doing?

James West:   Fantastic.

Ed Milewski:  Nice to meet you.

James West:   We’re curious about your company, Cannabics Pharmaceuticals.

Eyal Barad:   Yeah. What can I tell you about it?</

Chemesis International Inc (CNSX:CSI) is a new entry on the Canadian Securities Exchange, which began trading in July. The cannabis company is in a position to benefit from the new California regulations introduced on July 1 and is primed to increase the number of dispensaries carrying Chemesis products as dispensaries move toward compliance. Chemesis CEO Edgar Montero shares that the company will make an announcement soon about Latin American expansion and that Chemesis plans to build shareholder value in 2019 with real revenues. Chemesis recently raised $25 million in an equity financing with Alumina Partners and intends to use this investment to continue development.

James West:   Hey, welcome back to Midas Letter Live. My guess in this segment is Edgar Montero, the CEO of Chemesis International Inc., trading on the CSE under the symbol CSI. Edgar, welcome to our show.

Edgar Montero: How are you, James?

James West:   I’m great, thanks, how are you doing?

Edgar Montero: I’m fine, thank you. It’s a beautiful day.

James West:   Yeah. So you just started trading on the CSE on July 20th, and tell me about what’s your business?

Edgar Montero: Well, obviously we’re in the cannabis industry, that is safe to say, and we’r

Front Range Biosciences CFO and co-founder Nick Hofmeister outlines the company’s propagation methods to create disease-free, pesticide-free, certified true-to-type clones for hemp, cannabis, and coffee. While it can take four to six months to clean new stock in the initiation process, Front Range now has 170,000 plants in its inventory and can multiply that stock at a rate of 3 to 4 times every 6 to 8 weeks, depending on plant variety. As a result, Front Range fills a critical niche in the cannabis industry, by offering disease-free plant propagation. Front Range’s plant propagation are also perfect for home growers in Canada and Hofmeister anticipates Front Range working with retail dispensaries and consumers directly in the future.

James West:   Our guest in this moment right now is Nick Hofmeister. He’s the CFO and co-founder of Front Range Biosciences. This is a private company, Nick?

Nick Hofmeister:   It is a private company. We’ve been around for about two years, and have raised about $4.5 million into the company from venture capital.

Ed Milewski:  Where are you based?

Nick Hofmeister:   We’re in Lafayette, Colorado, just north of Denver and east of Boulder.

James West:   Okay.

Ed Milewski:  All right.

James West:   So your particular focus as it pertains to cannabis is, you specialized in tissue culture, and so is that basically propagating cannabis through cytokines and that kind of thing?

Nick Hofmeister:   It is a method of propagation that involves using sterile lab procedures to create disease-free, pesticide-free, and certified true-to-type clone. So these clones come out in the healthiest possible way, and then they’re delivered to cultivators to go into their grows. We do this for hemp, marijuana and now coffee.

James West:   Okay. For the process from which you initiate a clone process, or, rather, a tissue culture process, till you’re able to deliver a clone product to the grower?

Nick Hofmeister:   There are a few stages to the work that we do. The first stage is to bring the plants from the cultivator, or from our own library, into the tissue culture process; that’s called initiation. That cleanup process can take a while. It can take four to six months to get a plant into our process, into clean stock, and remove all disease, all pesticide, and certify that it is a true-to-type plant – it is the plant that you want it to be.

That process of four to six months is mainly driven by the fact that every single plant we’ve brought into our facility from our customers has at least one disease on it. Sometimes it’s two to five, all layered on top of each other. So that cleanup process can take

Cognetivity Neurosciences Ltd (CNSX:CGN) (FRA:1UB) CEO Dr. Sina Habibi demonstrates the company’s new diagnostic technology designed to detect dementia before symptoms manifest in a patient. Cognetivity’s product was created to assess the brain objectively using artificial intelligence and cutting edge neuroscience. Cognetivity’s app tests a patient’s speed, accuracy, and ability to recognize patterns in response to visual stimuli, creating a mental health assessment based on these responses.  Cognetivity envisions its product as part of the annual primary care assessment for patients above 55. Cognetivity believes its product can detect the disease 20-25 years earlier in its life cycle than conventional testing and could eventually be used as a diagnostic tool for similar diseases such as Alzheimer’s and Parkinson’s.

James West:   Hey, welcome back to Midas Letter Live. My guest this segment is Dr. Sina Habibi. He’s the CEO of Cognetivity Neurosciences Ltd, trades on the CSE under the symbol CGN. Sina, thank you for joining me.

Sina Habibi:  Thank you for having me.

Delta 9 Cannabis (CVE:NINE) (OTCMKTS:VRNDF) (FRA:V5D1) CEO John Arbuthnot talks with James West about Delta 9’s recent licensing agreement with Nanosphere Health Sciences. The partners plan to use patented technology to increase the uptake of cannabinoids in Delta 9 products. Arbuthnot explains Delta 9’s vertical integration strategy with regards to the recreational market, stating that the company aims to roll out retail locations in Winnipeg, Brandon, and Thompson by the end of the year. Once this retail framework is established, Delta 9 intends to look to Saskatchewan, Alberta, British Columbia, and Ontario for expansion opportunities. Delta 9 partnered with Fort Garry Brewing Company, Manitoba’s largest craft brewery, to produce Legal Lager Hemp Beer and the two companies are currently collaborating on developing non-alcoholic, cannabis-infused beverages.

James West:   Hey, welcome back to Midas Letter Live. My guest in this segment is John Arbuthnot. He is the CEO of Delta 9 Cannabis, trading on the TSX Venture under the symbol NINE. John, welcome to the show.

John Arbuthnot:    Thank you for having me.

James West:   Despite many technical difficulties, we’ve got you live here; I can’t believe it. John, we’ve talked to you a couple of times in the past and, you know, you’re based in Manitoba, right?

John Arbuthnot:    That’s correct.

James West:   And which fo

Planet 13 Holdings Inc (CNSX:PLTH) (OTCMKTS:PLNHF) CEO Robert Groesbeck reveals the company is in the midst of building its flagship location, and the world’s largest cannabis dispensary, just off the strip in Las Vegas. While Plant 13’s new superstore will boast dozens of different in-house and vendor-sourced cannabis varieties, the store will also act as a cannabis entertainment complex. Visitors will have the chance to experience traditional Las Vegas entertainment spaces such as ultra lounges as well as to try the latest in interactive gaming. Planet 13 is working with local officials to establish a regulatory framework that will allow consumers to use cannabis products while enjoying Planet 13’s entertainment offerings.

James West:   Hey, welcome back to Midas Letter Live. My guest in this segment, coming to us from Las Vegas, Nevada, is Robert Groesbeck. He is the CEO of Planet 13 Holdings, trading on the CSE under the symbol PLTH. Robert, welcome to our humble show.

Robert Groesbeck:  thanks, James. It’s great to be with you.

James West:   So Robert, let’s start with an overview: what does Planet 13 Holdings actually do?

Robert Groesbeck:  We’re a vertically

Province Brands CEO Dooma Wendschuh shares the company’s go-public financing strategy with James West and Ed Milewski. When operating at full capacity, Province Brands will be the largest cannabis brewery in the world, producing 60 million bottles of cannabis beer annually. Province Brands is uniquely situated as a cannabis brewer because it has both brewing and cannabis licenses, which allows the company to act as a contract facility in addition to producing its own branded products. Unlike other cannabis beers, Province Brands’ low-calorie product is brewed from the cannabis plant itself, providing consumers with an authentic, craft industry experience.

James West:   This whole economy based around cannabis is taking on a head of steam, and nobody can represent that evolution more succinctly than my good friend Dooma Wendschuh, who also happens to be the CEO and founder of Province Brands. Dooma, welcome back.

Dooma Wendschuh:   It’s great to be here. Thank you for having me, it’s an honour.

James West:   Dooma, you are making incredible strides with Province Brands; you’ve got a prototype packaged beer here, and that looks like a beer –

Ed Milewski:  Is that the right spot right there?

James West:   That’s the right spot. So it’s obvious you’re making great progress. You’ve closed financing, you’ve got a go-public strategy that’s unfolding.

Dooma Wendschuh:   That’s correct, yeah. We just announced that we closed our Series A round. We raised $10.9 million CDN. Now, the total that we’ve raised since starting the company is around $16 million CDN. We have announced that we will be taking the company public, ideally before the end of the year, and we are planning our Series B, which will be our go-public round, which I mentioned actually before on your show will be underwritten by Paradigm as well as a few other banks that will be joining the group that will be raising the capital.

James West:   Great.

Dooma Wendschuh:   It’s coming together; we look to be raising about $30 million concurrent with our public listing.

James West:   Wow, okay. So, is that enough to build the brewery?

Dooma Wendschuh:   It’ll get us started, let’s put it that way. We can get a small brewery and we can increase capacity, and when we’re up and running at full capacity, we’ll be 175,000 hectolitres, which is roughly 60 million bottles of cannabis beer per year, and we’ll be able to scale up from that, given success. But we’ll be the largest cannabis brewery in the world, and we will be also a contract

The Green Organic Dutchman Holdings Ltd (TSE:TGOD) (OTCMKTS:TGODF) (FRA:01GA) CEO Brian Athaide shares the company’s seed-to-sale vertical integration strategy. TGOD has already successfully vertically-integrated its operations in Jamaica, with its first retail store opening in July and plans to open 5 more locations across the country by the end of the year. Athaide reveals the company plans to take the same approach when its Canadian production begins in 2019. Funded for 170,000 kilograms of production and 1.4 million square feet of cultivation in Ontario, Quebec, and Jamaica, Green Organic Dutchman is positioned to be a major player in the cannabis industry. Athaide discusses how the company’s recent partnership with industry leader Aurora Cannabis (TSE:ACB) helping Green Organic Dutchman to learn and grow more efficiently.

James West:   Hi everybody, hello audience and everybody back there. Welcome back to Midas Letter Live. My guest in this segment, at long last, is the CEO of The Green Organic Dutchman, Brian Athaide.

Brian Athaide: Athaide.

Aben Resources Ltd (CVE:ABN) (OTCMKTS:ABNAF) (FRA:E2L2) President Jim Pettit discusses their catalyzing, recent discovery at their Forrest Kerr project located in British Columbia’s Golden Triangle. Surrounded by an abundance of other high profile mines, Aben has struck multiple high-grade zones with 62.4 grams per ton gold from over 6 metres and 38.7 grams per ton over 10 metres assay findings and still have more drill results on the horizon. Pettit outlines their recent private placement led by Eric Sprott and the consequential, future drilling plans before and after the upcoming winter.

James West: Hey, welcome back to Midas Letter Live. My guest this segment is Jim Pettit, he’s the President of Aben Resources Limited trading on the TSX Venture under the symbol ABN. Jim, welcome to the show.

Jim Pettit: Thank you very much.

James West: Now